Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

被引：7
|
作者：
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Washington Univ, Sch Med, St Louis, MO 14263 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA
[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[8] Mayo Clin, Rochester, MN USA
[9] City Hope Natl Med, Duarte, CA USA
[10] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
[11] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[12] Univ Iowa, Iowa City, IA USA
[13] Kite, Santa Monica, CA USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3003
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Ghobadi, Armin
    Miklos, David B.
    Lekakis, Lazaros J.
    Spooner, Clare
    Kim, Jenny J.
    Miao, Harry
    Xue, Allen Xiaodong
    Zheng, Yan
    Locke, Frederick L.
    BLOOD, 2023, 142
  • [22] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
    Reshef, Ran
    Miklos, David B.
    Timmerman, John M.
    Jacobson, Caron A.
    Bennani, Nabila N.
    Rossi, John M.
    Sherman, Marika
    Zheng, Lianqing
    Sun, Jennifer
    Palluconi, Gabrielle
    Kim, Jenny J.
    Jain, Michael D.
    BLOOD, 2019, 134
  • [23] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
    Neelapu, Sattva S.
    Ghobadi, Armin
    Jacobson, Caron A.
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan O.
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John M.
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick J.
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Chavez, Julio C.
    Herrera, Alex F.
    Xue, Allen
    Jiang, Yizhou
    Bot, Adrian
    Rossi, John M.
    Kim, Jenny J.
    Go, William Y.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [24] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
    Neelapu, Sattva S.
    Ghobadi, Armin
    Jacobson, Caron A.
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Chavez, Julio C.
    Herrera, Alex F.
    Xue, Allen
    Jiang, Yizhou
    Bot, Adrian
    Rossi, John M.
    Kim, Jenny J.
    Go, William Y.
    Locke, Frederick L.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [25] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
    Zhang, Muchen
    Fang, Ying
    Xu, Pengpeng
    Cheng, Shu
    Wang, Li
    Zhao, Wei-Li
    BLOOD, 2018, 132
  • [26] Outcomes by Prior Lines of Therapy in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 11 - 13
  • [27] Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
    Logue, Jennifer Marilyn
    Krivenko, Gabriel S.
    Larson, Victoria
    Bachmeier, Christina A.
    Chavez, Julio C.
    Davila, Marco L.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien D.
    Pinilla-Ibarz, Javier
    Shah, Bijal D.
    Dholaria, Bhagirathbhai R.
    Jain, Michael D.
    Locke, Frederick Lundry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [29] Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
    Locke, Frederick L.
    Ghobadi, Armin
    Lekakis, Lazaros J.
    Miklos, David B.
    Jacobson, Caron A.
    Jacobsen, Eric
    Braunschweig, Ira
    Oluwole, Olalekan O.
    Siddiqi, Tanya
    Lin, Yi
    Reagan, Patrick M.
    Farooq, Umar
    Deol, Abhinav
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen
    Go, William Y.
    Neelapu, Sattva S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S276
  • [30] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
    Kenderian, Saad S.
    Oluwole, Olalekan O.
    McCarthy, Philip L.
    Reshef, Ran
    Shiraz, Parveen
    Ahmed, Omar
    Le Gall, John
    Nahas, Myrna
    Tang, Lily
    Neelapu, Sattva S.
    BLOOD, 2020, 136
12345